Signal Transduction and Targeted Therapy (Apr 2023)

Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex

  • Sihui Cai,
  • Chenqiu Zhang,
  • Zhen Zhuang,
  • Shengnan Zhang,
  • Ling Ma,
  • Shuai Yang,
  • Tao Zhou,
  • Zheyu Wang,
  • Weihong Xie,
  • Shouheng Jin,
  • Jincun Zhao,
  • Xiangdong Guan,
  • Jianfeng Wu,
  • Jun Cui,
  • Yaoxing Wu

DOI
https://doi.org/10.1038/s41392-023-01420-9
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Currently, the incidence and fatality rate of SARS-CoV-2 remain continually high worldwide. COVID-19 patients infected with SARS-CoV-2 exhibited decreased type I interferon (IFN-I) signal, along with limited activation of antiviral immune responses as well as enhanced viral infectivity. Dramatic progresses have been made in revealing the multiple strategies employed by SARS-CoV-2 in impairing canonical RNA sensing pathways. However, it remains to be determined about the SARS-CoV-2 antagonism of cGAS-mediated activation of IFN responses during infection. In the current study, we figure out that SARS-CoV-2 infection leads to the accumulation of released mitochondria DNA (mtDNA), which in turn triggers cGAS to activate IFN-I signaling. As countermeasures, SARS-CoV-2 nucleocapsid (N) protein restricts the DNA recognition capacity of cGAS to impair cGAS-induced IFN-I signaling. Mechanically, N protein disrupts the assembly of cGAS with its co-factor G3BP1 by undergoing DNA-induced liquid-liquid phase separation (LLPS), subsequently impairs the double-strand DNA (dsDNA) detection ability of cGAS. Taken together, our findings unravel a novel antagonistic strategy by which SARS-CoV-2 reduces DNA-triggered IFN-I pathway through interfering with cGAS-DNA phase separation.